U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H37N5O3.ClH
Molecular Weight 564.118
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DORAMAPIMOD HYDROCHLORIDE

SMILES

Cl.CC1=CC=C(C=C1)N2N=C(C=C2NC(=O)NC3=CC=C(OCCN4CCOCC4)C5=C3C=CC=C5)C(C)(C)C

InChI

InChIKey=WVPYACKQYUYZGC-UHFFFAOYSA-N
InChI=1S/C31H37N5O3.ClH/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35;/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C31H37N5O3
Molecular Weight 527.6572
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15755732 | https://www.ncbi.nlm.nih.gov/pubmed/11937566 | https://trials.boehringer-ingelheim.com/trial_results/clinical_trials_overview/clinical_trial_result.c=n.i=68.html

Doramapimod (BIRB-796) is a p38 MAPK inhibitor, relatively potent against alpha isoform. Oral doramapimod exerts anti-inflammatory potential in humans in vivo. Doramapimod has entered clinical trials for the treatment of autoimmune diseases.

Originator

Curator's Comment: # Boehringer Ingelheim Pharmaceuticals

Approval Year

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures.
2007 Nov 8
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Gene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases.
2013 Oct
Patents

Sample Use Guides

A randomised, parallel, double-blind, placebo-controlled study investigated efficacy and safety of different doses (5, 10, 20 and 30 mg) of doramapimod (BIRB-796) administered twice a day orally over 4 weeks in patients with active rheumatoid arthritis
Route of Administration: Oral
1-1000 nM doramapimod (BIRB-796) inhibited LPS-induced phosphorylation of p38 MAPK in human peripheral blood mononuclear cells in a dose-related fashion
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:31:13 UTC 2023
Edited
by admin
on Sat Dec 16 10:31:13 UTC 2023
Record UNII
X9BAM4UVNT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DORAMAPIMOD HYDROCHLORIDE
Common Name English
UREA, N-(3-(1,1-DIMETHYLETHYL)-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL)-N'-(4-(2-(4-MORPHOLINYL)ETHOXY)-1-NAPHTHALENYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
X9BAM4UVNT
Created by admin on Sat Dec 16 10:31:13 UTC 2023 , Edited by admin on Sat Dec 16 10:31:13 UTC 2023
PRIMARY
CAS
1283526-53-3
Created by admin on Sat Dec 16 10:31:13 UTC 2023 , Edited by admin on Sat Dec 16 10:31:13 UTC 2023
PRIMARY
PUBCHEM
68107492
Created by admin on Sat Dec 16 10:31:13 UTC 2023 , Edited by admin on Sat Dec 16 10:31:13 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY